Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Cipla Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

(-) Cancellation by sponsor (239)
ARTG (460)
Cancellation or suspension (79)
Prescription medicine registration (45)
Cancellation for failure to pay annual charge (17)
Australian public assessment report (AusPar) (5)
Prescription medicine decision summary (4)
Prescription medicine evaluation (1)

Date

2025 (44)
2024 (35)
2023 (42)
2022 (22)
2021 (12)
2020 (17)
2018 (26)
2017 (28)
2016 (5)
2015 (8)

Search

Filters applied:

Cancellation by sponsor

Clear all

Sponsor content

239 result(s) found, displaying 11 to 20

PHARMACY CARE ORAL REHYDRATION POWDER oral powder sachet Cancelled under Section 30(1)(c) of the Act

30 June 2025

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
AMCAL ORAL REHYDRATION POWDER oral powder sachet Cancelled under Section 30(1)(c) of the Act

30 June 2025

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
TRUST DEWORM mebendazole 100mg chewable tablet blister pack Cancelled under Section 30(1)(c) of the Act

30 June 2025

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
ALLERID cetirizine hydrochloride 5 mg/5 mL oral solution bottle Cancelled under Section 30(1)(c) of the Act

30 June 2025

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
Suspended from ARTG - CIPLA REFLUX RELIEF ranitidine (as hydrochloride) 150mg tablet strip pack Cancelled under Section 30(1)(c) of the Act

30 June 2025

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
BEVACIPTIN bevacizumab 400 mg/16 mL concentrated solution for infusion vial Cancelled under Section 30(1)(c) of the Act

30 June 2025

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
BEVACIPTIN bevacizumab 100 mg/4 mL concentrated solution for infusion vial Cancelled under Section 30(1)(c) of the Act

30 June 2025

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
LACORESS lacosamide 200 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

30 June 2025

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
LACORESS lacosamide 50 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

30 June 2025

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd
LACORESS lacosamide 100 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

30 June 2025

Cancellation by sponsor

Requested by Cipla Australia Pty Ltd

Pages

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.